Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

	rmaceuticals Inc										
Form 4	2017										
January 05, 2									OMB A	PPROVAL	
FORM	UNITED	STATES		RITIES A			NGE	COMMISSION		3235-0287	
Check th if no long subject to Section 1 Form 4 of Form 5 obligatio may cont See Instr 1(b).	ger 5 16. 5 5 5 5 5 5 5 5 5 5 5 5 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940								January 31, 2005 average urs per . 0.5	
(Print or Type]	Responses)										
1. Name and A FAMBROU	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol Dicerna Pharmaceuticals Inc [DRNA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O DICER PHARMAC CAMBRID		3. Date of Earliest Transaction (Month/Day/Year) 01/03/2017					X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer				
				endment, Da onth/Day/Yea	-	ıl		 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
CAMBRID	GE, MA 02140							Person		1 0	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
				Code V	Amount	(D)	Price	(mour, 5 and 4)			
Reminder: Rep	oort on a separate line	e for each cla	ass of sec	urities benef	ficially ow	ned di	rectly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Dat Conversion (Month/Day/Year) or Exercise Price of Derivative Security		3A. Deemed Execution D any (Month/Day/	ate, if	Code		5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exer Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 2.97	01/03/2017			А		225,000		<u>(1)</u>	01/03/2027	Common Stock	225,00
Reporting Owners												
Re	er Name / Address	Relationships										
Reporting Owner Mane / Address			Di	irector	10% (Owne	er Office	er		Other		
FAMBROUGH DOUGLAS C/O DICERNA PHARMACEUTICAI 87 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140			S, INC.	X	Chief Executive				ecutive Offi	icer		
Signat	ures											
/s/ John B. Green,			01/05/2017									

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

01/05/2017 attorney-in-fact Date

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the (1) reporting person's continued service with the issuer through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.